Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Ibrahim A. Shalaby

Oncology
Providence
4101 22nd Place, 
Lubbock, TX 
Accepting New Patients

Experienced in WT1-Related Wilms Tumor Syndromes
Providence
4101 22nd Place, 
Lubbock, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ibrahim Shalaby is an Oncologist in Lubbock, Texas. Dr. Shalaby is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Pleuropulmonary Blastoma. Dr. Shalaby is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
Nor-Lea Hospital District
Grace Surgical Hospital
University Medical Center
Covenant Medical Center
Covenant Childrens Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
FirstCare
  • HMO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Sky Community Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER COMMERCIAL
View 15 Less Insurance Carriers -

Locations

4101 22nd Place, Lubbock, TX 79410
Call: 806-725-8000

Additional Areas of Focus

Dr. Shalaby has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


8 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma
Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma
Enrollment Status: Terminated
Publish Date: August 27, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

2 Total Publications

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 08, 2018
View All 2 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Thomas E. Hutson
Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Thomas E. Hutson
Oncology | Hematology

Texas Tech University Health Sciences Center Lubbock

602 Indiana Ave, 
Lubbock, TX 
 (1.3 miles away)
806-743-1842
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Hutson is an Oncologist and a Hematologist in Lubbock, Texas. Dr. Hutson is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Adult Soft Tissue Sarcoma, and Renal Cell Carcinoma (RCC). Dr. Hutson is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. David R. Close
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. David R. Close
Oncology
4101 22nd Place, 
Lubbock, TX 
 (0.1 miles away)
806-725-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Close is an Oncologist in Lubbock, Texas. Dr. Close is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Paget Disease of the Breast, Inflammatory Breast Cancer, Breast Cancer, and Familial Colorectal Cancer. Dr. Close is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Lukman A. Tijani
Hematology Oncology | Oncology | Hematology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Lukman A. Tijani
Hematology Oncology | Oncology | Hematology

Texas Tech University Health Sciences Center Lubbock

602 Indiana Ave, 
Lubbock, TX 
 (1.3 miles away)
806-743-3150
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lukman Tijani is a Hematologist Oncology specialist and an Oncologist in Lubbock, Texas. Dr. Tijani is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Neuroendocrine Tumor, Bone Marrow Aspiration, and Endoscopy. Dr. Tijani is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shalaby's expertise for a condition
ConditionClose
    • Distinguished
    • Angiosarcoma
      Dr. Shalaby is
      Distinguished
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Astrocytoma
      Dr. Shalaby is
      Distinguished
      . Learn about Astrocytoma.
      See more Astrocytoma experts
    • Atypical Teratoid Rhabdoid Tumor (ATRT)
      Dr. Shalaby is
      Distinguished
      . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
      See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
    • Breast Cancer
      Dr. Shalaby is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Colorectal Cancer
      Dr. Shalaby is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Embryonal Tumor with Multilayered Rosettes
      Dr. Shalaby is
      Distinguished
      . Learn about Embryonal Tumor with Multilayered Rosettes.
      See more Embryonal Tumor with Multilayered Rosettes experts
    View All 16 Distinguished Conditions
    • Advanced
    • Adult Soft Tissue Sarcoma
      Dr. Shalaby is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Shalaby is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Anal Cancer
      Dr. Shalaby is
      Advanced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Bone Tumor
      Dr. Shalaby is
      Advanced
      . Learn about Bone Tumor.
      See more Bone Tumor experts
    • Brain Tumor
      Dr. Shalaby is
      Advanced
      . Learn about Brain Tumor.
      See more Brain Tumor experts
    • Breast Cancer in Men
      Dr. Shalaby is
      Advanced
      . Learn about Breast Cancer in Men.
      See more Breast Cancer in Men experts
    View All 37 Advanced Conditions
    • Experienced
    • Acinic Cell Carcinoma of Salivary Glands
      Dr. Shalaby is
      Experienced
      . Learn about Acinic Cell Carcinoma of Salivary Glands.
      See more Acinic Cell Carcinoma of Salivary Glands experts
    • Adenoid Cystic Carcinoma
      Dr. Shalaby is
      Experienced
      . Learn about Adenoid Cystic Carcinoma.
      See more Adenoid Cystic Carcinoma experts
    • Alveolar Soft Part Sarcoma
      Dr. Shalaby is
      Experienced
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    • Ampullary Cancer
      Dr. Shalaby is
      Experienced
      . Learn about Ampullary Cancer.
      See more Ampullary Cancer experts
    • Anaplastic Large Cell Lymphoma
      Dr. Shalaby is
      Experienced
      . Learn about Anaplastic Large Cell Lymphoma.
      See more Anaplastic Large Cell Lymphoma experts
    • Anaplastic Thyroid Cancer
      Dr. Shalaby is
      Experienced
      . Learn about Anaplastic Thyroid Cancer.
      See more Anaplastic Thyroid Cancer experts
    View All 84 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved